Overall impact
B (76)

Commentary

Alvotech is a strong overall performer. With a 'B' rating of 76.5 for overall impact (91st percentile compared to all companies), Alvotech ranks 36th out of 250 industry peers, behind Assembly Biosciences, Haleon, MedAvail and 32 others, and ahead of Catalyst Pharmaceuticals, Agios Pharmaceuticals, Pharmaron Beijing H and 211 others. On top material causes for Alvotech's industry (Pharmaceuticals), Alvotech performs well in Disease Eradication (96.0 score), Child and Maternal Health (95.2), Access to Affordable Healthcare (95.4) and 27 other causes where it received an 'A' score and performs poorly in Accountable Institutions (33.4 score), Accountable Institutions (33.4), Accountable Institutions (33.4) and 6 other causes where it received a 'D' or 'F' score.
Screens
Fur
Impact
Cause ALVO
Peer rank
Overall impact

Log in to view this information

Screens
Fur
Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2013
Employees
1,279
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Luxembourg
Share classes
ALVO
Description
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.
Material causes
Ethos considers the following causes material for Alvotech, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.